Lista de obras -

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.

artículo científico publicado en 2017

Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors ⬇️

artículo científico publicado el 14 de diciembre de 2012

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

artículo científico publicado en 2017

Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma ⬇️

artículo científico publicado el 16 de abril de 2012

Bridging the gap: metabolic and endocrine care of patients during transition

artículo científico publicado en 2016

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

artículo científico publicado en 2015

Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

artículo científico publicado en 2015

Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study

artículo científico publicado en 2010

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

artículo científico publicado en 2010

Combination treatment with somatostatin analogues and pegvisomant in acromegaly

artículo científico publicado en 2011

Combined treatment of somatostatin analogues with pegvisomant in acromegaly

artículo científico publicado en 2016

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients ⬇️

artículo científico publicado el 1 de septiembre de 2011

Des-Acyl Ghrelin: A Metabolically Active Peptide ⬇️

artículo científico publicado el 25 de abril de 2013

Diagnostic value of a ghrelin test for the diagnosis of GH deficiency after subarachnoid hemorrhage ⬇️

artículo científico publicado el 14 de septiembre de 2013

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

artículo científico publicado en 2017

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study

scientific article published on 12 October 2018

Emotional Distress in 652 Dutch Very Long-term Survivors of Childhood Cancer, Using the Hospital Anxiety and Depression Scale (HADS) ⬇️

artículo científico publicado el 1 de octubre de 2013

Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia

artículo científico publicado en 2013

Extra-hepatic Acromegaly

artículo científico publicado en 2013

Gonadal function recovery in very long-term male survivors of childhood cancer ⬇️

artículo científico publicado el 5 de enero de 2013

How to Position Pasireotide LAR Treatment in Acromegaly

artículo científico publicado en 2019

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

artículo científico publicado en 2017

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

scientific article published on 15 April 2014

Inactive lifestyles and sedentary behavior in persons with chronic aneurysmal subarachnoid hemorrhage: evidence from accelerometer-based activity monitoring

artículo científico publicado en 2017

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

artículo científico publicado en 2015

Long-Term Nephrotoxicity in Adult Survivors of Childhood Cancer ⬇️

artículo científico publicado el 14 de febrero de 2013

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy

artículo científico

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

artículo científico publicado en 2014

Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin

artículo científico

Medical approach to pituitary tumors

artículo científico

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues

artículo científico publicado en 2009

Modulation of Glucocorticoid Metabolism by the GH-IGF-I Axis ⬇️

artículo científico publicado el 16 de diciembre de 2010

Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer ⬇️

artículo científico publicado el 14 de agosto de 2012

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

artículo científico publicado en 2019

Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors

artículo científico publicado el 1 de febrero de 2013

Pegvisomant Treatment in Acromegaly

artículo científico publicado en 2015

Pegvisomant and not somatostatin receptor ligands (SRLs) is first line medical therapy for acromegaly

artículo científico publicado en 2020

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.

artículo científico publicado en 2015

Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions

scientific article published on 13 March 2018

Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study

artículo científico publicado en 2014

Pregnancy and acromegaly.

artículo científico publicado en 2017

Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review

scientific article published on 28 July 2009

Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration W

artículo científico publicado en 2016

Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the [...]

artículo científico publicado en 2017

Review of current and emerging treatment options in acromegaly

artículo científico publicado en 2015

Risk factors for subsequent endocrine-related cancer in childhood cancer survivors

artículo científico publicado en 2016

Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do?

artículo científico

Soluble Klotho: a possible predictor of quality of life in acromegaly patients

artículo científico publicado en 2020

Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects

artículo científico publicado en 2016

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

artículo científico publicado en 2016

Somatostatin analog and pegvisomant combination therapy for acromegaly

artículo científico publicado en 2009

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

artículo científico publicado en 2016

T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly

artículo científico publicado en 2020

T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

artículo científico publicado en 2016

The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.

artículo científico publicado en 2016

The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens

artículo científico publicado en 2017

The limited screening value of insulin‐like growth factor‐i as a marker for alterations in body composition in very long‐term adult survivors of childhood cancer ⬇️

artículo científico publicado el 11 de diciembre de 2011

The metabolic syndrome in adult survivors of childhood cancer, a review

artículo científico publicado en 2010

The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study

scientific article published on 24 April 2020

Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors

artículo científico publicado en 2012

Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states

artículo científico publicado en 2017

Very long-term sequelae of craniopharyngioma.

artículo científico publicado en 2017

What is active acromegaly and which parameters do we have? ⬇️

artículo científico publicado el 1 de mayo de 2012

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

scientific article published on 22 February 2016

X-linked acrogigantism syndrome: clinical profile and therapeutic responses

artículo científico publicado en 2015

β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.

artículo científico publicado en 2013

Lista de obras de

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.

Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors ⬇️

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma ⬇️

Bridging the gap: metabolic and endocrine care of patients during transition

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

Combination treatment with somatostatin analogues and pegvisomant in acromegaly

Combined treatment of somatostatin analogues with pegvisomant in acromegaly

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients ⬇️

Des-Acyl Ghrelin: A Metabolically Active Peptide ⬇️

Diagnostic value of a ghrelin test for the diagnosis of GH deficiency after subarachnoid hemorrhage ⬇️

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study

Emotional Distress in 652 Dutch Very Long-term Survivors of Childhood Cancer, Using the Hospital Anxiety and Depression Scale (HADS) ⬇️

Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia

Extra-hepatic Acromegaly

Gonadal function recovery in very long-term male survivors of childhood cancer ⬇️

How to Position Pasireotide LAR Treatment in Acromegaly

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

Inactive lifestyles and sedentary behavior in persons with chronic aneurysmal subarachnoid hemorrhage: evidence from accelerometer-based activity monitoring

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

Long-Term Nephrotoxicity in Adult Survivors of Childhood Cancer ⬇️

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin

Medical approach to pituitary tumors

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues

Modulation of Glucocorticoid Metabolism by the GH-IGF-I Axis ⬇️

Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer ⬇️

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors

Pegvisomant Treatment in Acromegaly

Pegvisomant and not somatostatin receptor ligands (SRLs) is first line medical therapy for acromegaly

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.

Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions

Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study

Pregnancy and acromegaly.

Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review

Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration W

Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the [...]

Review of current and emerging treatment options in acromegaly

Risk factors for subsequent endocrine-related cancer in childhood cancer survivors

Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do?

Soluble Klotho: a possible predictor of quality of life in acromegaly patients

Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

Somatostatin analog and pegvisomant combination therapy for acromegaly

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly

T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.

The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens

The limited screening value of insulin‐like growth factor‐i as a marker for alterations in body composition in very long‐term adult survivors of childhood cancer ⬇️

The metabolic syndrome in adult survivors of childhood cancer, a review

The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study

Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors

Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states

Very long-term sequelae of craniopharyngioma.

What is active acromegaly and which parameters do we have? ⬇️

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

X-linked acrogigantism syndrome: clinical profile and therapeutic responses

β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.